中国药物警戒 ›› 2022, Vol. 19 ›› Issue (9): 1015-1018.
DOI: 10.19803/j.1672-8629.2022.09.17

• 安全与合理用药 • 上一篇    下一篇

吡格列酮对2型糖尿病患者血浆脂联素影响的Meta分析

穆思聪1, 王卓2, 卢俊阳1, 纪立伟3,*, 柳鑫1,#   

  1. 1首都医科大学附属北京天坛医院药学部,北京 100070;
    2首都医科大学附属北京天坛医院内科学系,北京 100070;
    3北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,北京 100730
  • 收稿日期:2021-09-02 出版日期:2022-09-15 发布日期:2022-09-16
  • 通讯作者: *纪立伟,女,主任药师,临床药学与医院药物警戒。E-mail: jlw1228@sina.com;#为共同通信作者。
  • 作者简介:穆思聪,男,药师,医院药学。
  • 基金资助:
    国家重点研发计划（2020YFC2008305）

Effects of pioglitazone on plasma adiponectin in patients with type 2 diabetes mellitus: a Meta-analysis

MU Sicong1, WANG Zhuo2, LU Junyang1, JI Liwei3,*, LIU Xin1,#   

  1. 1Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;
    2Department of Internal Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;
    3Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
  • Received:2021-09-02 Online:2022-09-15 Published:2022-09-16

PDF (PC)

72

摘要： 目的 通过Meta分析,探讨吡格列酮对2型糖尿病患者血浆脂联素的作用。方法 系统检索万方数据、中国知网、PubMed、the Cochrane Library与Embase数据库（建库至2021年4月30日）吡格列酮治疗2型糖尿病调节脂联素的随机对照试验,依据PRISMA标准（Meta分析报告标准）进行文献筛选与数据提取,采用Cochrane标准进行质量评估,使用RevMan 5.3和Stata 14.0软件进行数据统计与分析。结果 纳入10项随机对照临床试验,分析结果显示,与安慰剂相比,给予吡格列酮治疗能够显著升高血浆脂联素含量（8.65 μg·mL-1,95% CI,7.18 ~10.12 μg·mL-1）。与其他类降糖药物相比,吡格列酮治疗升高脂联素作用可能更为明显（4.92 μg·mL-1,95% CI, 3.27 ~6.58 μg·mL-1）。结论 与安慰剂或其他类降糖药物相比,吡格列酮能够升高2型糖尿病患者的血浆脂联素含量。

关键词: 脂联素, 吡格列酮, 2型糖尿病, 随机对照临床试验, Meta分析

Abstract: Objective To investigate the impact of pioglitazone on plasma adiponectin levels in patients with type 2 diabetes mellitus through meta-analysis. Methods Wanfang, CNKI, PubMed, the Cochrane Library and Embase were systematically searched for randomized controlled trials of pioglitazone in treatment of type 2 diabetes modulating adiponectin from the establishment to April 30, 2021. Literature selection and data extraction were conducted according to the PRISMA criteria. Quality assessment was conducted according to the Cochrane criteria. Data analysis was done with Revman 5.3 and Stata 14.0 software. Results Ten randomized controlled clinical trials were included. The analysis results demonstrated that pioglitazone treatment significantly increased plasma adiponectin levels by 8.65 μg·mL-1 (95% CI, 7.18~10.12 μg·mL-1) compared with placebo. Pioglitazone treatment showed a stronger effect on increasing adiponectin concentrations by 4.92 μg·mL-1 (95% CI, 3.27~6.58 μg·mL-1 ) compared with other oral antidiabetic agents. Conclusion Pioglitazone could increase plasma adiponectin concentrations in patients with type 2 diabetes mellitus compared to placebo or other oral antidiabetic agents.

Key words: adiponectin, pioglitazone, type 2 diabetes mellitus, randomized controlled clinical trials, Meta-analysis

中图分类号: